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ABSTRACT: Background. Stereotactic radiosurgery is widely applied to
deliver additional dose to head and neck tumors. However, its safety and
efficacy remains equivocal.
Methods. One hundred eighty-four patients with primary head and neck
cancers treated between January 1990 and August 2012 with Gamma
Knife stereotactic radiosurgery were retrospectively reviewed.
Results. Two hundred fifteen sites were treated with Gamma Knife ste-
reotactic radiosurgery among 184 patients. Fifty-one percent of patients
received concurrent external beam radiotherapy (EBRT), 72% had prior
surgery, and 46% received chemotherapy. Most (44%) had squamous
cell carcinoma and most patients (65%) were treated for recurrent dis-
ease. With a median follow-up of 17.3 months, 12-month local control
was 82%. Late effects occurred in 59 patients with the most common
being temporal lobe necrosis (15 patients).
Conclusion. Radiosurgery can provide tumor control for patients with
head and neck cancers involving the skull base. Long-term follow-up is
important in survivors to identify late effects. VC 2014 Wiley Periodicals,
Inc. Head Neck 37: 1557–1562, 2015
KEY WORDS: head and neck malignancy, stereotactic radiosurgery,
late effects, boost, chemoradiation
INTRODUCTION
Stereotactic radiosurgery has been applied to head and
neck cancers in the setting of multimodality treatment,
including primary radiotherapy of residual disease postop-
eratively or as part of primary chemoradiotherapy. It has
also been used as salvage treatment for recurrence after
definitive treatment. However, long-term outcomes are
not well defined for stereotactic radiosurgery in the head
and neck cancer population.
Even after aggressive initial therapy, local recurrence is
a major issue for primary locally advanced head and neck
cancers. Radiosurgery offers the ability to dose escalate
in sensitive areas, especially at the base of the skull. This
is an attractive option because stereotactic radiosurgery
can be delivered with great precision and conformality to
the site in question. With the addition of stereotactic
radiosurgery to the treatment of patients who have already
undergone multiple modalities, including surgery, chemo-
therapy, and external beam radiotherapy (EBRT), the
potential for side effects may also increase. The benefit
of stereotactic radiosurgery needs to be balanced with the
potential for toxicity.
MATERIALS AND METHODS
Between January 1, 1990, and August 1, 2012, 375
patients were treated in the head and neck region with
Gamma Knife stereotactic radiosurgery at the Mayo
Clinic. This population excluded all patients who were
treated for intracranial parenchymal brain disease. Only
patients with head and neck cancers (184 patients with
nasopharynx, nasal cavity/paranasal sinuses, oral cavity,
oropharynx, hypopharynx, larynx, salivary gland, and
skin) were retrospectively reviewed. Information was col-
lected on patient age, sex, histology, stereotactic radiosur-
gery site treated, tumor grade, treatment intent, primary
versus recurrent versus metastatic disease, concurrent and
prior EBRT, and chemotherapy treatment. Tumor staging
was not consistently collected for most patients as many
were referred from outside institutions. This was espe-
cially true for patients who presented with recurrent dis-
ease and had their primary treatment and initial staging
performed at an outside institution. Local control, distant
progression, radiographic response to treatment, and late
toxicity were also reviewed. Gamma Knife stereotactic
radiosurgery parameters were recorded for each patient,
including marginal dose (minimum tumor dose), isodose
prescription line, maximum diameter treated, treatment
volume, number of isocenters treated, and maximum
dose.
Descriptive statistics were performed using JMP soft-
ware version 9.01 (SAS Institute, Cary, NC). Median
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progression-free survival, overall survival, and follow-up
from the date of Gamma Knife stereotactic radiosurgery
treatment were also calculated. Progression-free survival
was defined as any progression (local, regional ‘nodal’, or
distant) from the date of Gamma Knife stereotactic radio-
surgery treatment. Local failure was defined as in-field
progression over serial imaging with CT or MRI. This
study was approved by the Mayo Clinic Institutional
Review Board. In compliance with Minnesota State stat-
utes, all living patients consented to the review of their
medical records for research purposes.
Although most data were available in a prospectively
collected Mayo Clinic stereotactic radiosurgery database,
all data were verified by retrospective medical chart
review. Additional information was gathered from the
electronic medical records for follow-up visits and sur-
veillance imaging. The recording of late effects was based
on physician assessment and documentation in the elec-
tronic medical record. The definition of late toxicity was
any adverse event related to the stereotactic radiosurgery
treatment site (side effects attributed to EBRT outside of
the stereotactic radiosurgery site were excluded). Adverse
events were graded using the Common Terminology Cri-
teria for Adverse Events version 4.0 (National Cancer
Institute, published June 14, 2010).
Our general Gamma Knife stereotactic radiosurgery
treatment entailed patients being consented for stereotac-
tic radiosurgery as same-day out-patient surgery. Patients
presented for placement of a rigid head frame under local
anesthetic by neurosurgery. Usual practice involved IV
placement, sublingual Ativan 1 mg before head frame
placement, and a single dose of dexamethasone 8 mg PO/
IV immediately after Gamma Knife stereotactic radiosur-
gery. With frames in place, fine-cut gadolinium enhanced
MRIs (1 mm slice T1 sequence) were performed through
the region of interest, transferred to Leksell GammaPlan
and used for treatment planning. In patients where tumors
were close to the cochlea or optic structures, fine slice
CT scans were also performed and fused with the plan-
ning MRI. Patients were observed for 2 hours post-
stereotactic radiosurgery and then discharged. No patients
required overnight hospital stays. Patients who were
receiving Gamma Knife stereotactic radiosurgery as a
boost in addition to EBRT had their external beam treat-
ments held for that day.
RESULTS
Patient demographics
A total of 215 sites were treated with Gamma Knife
stereotactic radiosurgery in 184 patients during the study
period (Table 1). Most patients were men (115 of 184;
63%) and the majority was treated for head and neck
squamous cell carcinoma (81 of 184; 44%). Most sites
treated with stereotactic radiosurgery were for recurrent
disease (139 of 215; 65%) with stereotactic radiosurgery
used as a boost in addition to EBRT (105 of 215; 49%).
The timing of the Gamma Knife stereotactic radiosurgery
boost was mostly immediately before or early in the
EBRT course (first 1–4 weeks; 82 of 109; 75%). More
than 70% of patients had head and neck surgeries before
their stereotactic radiosurgery treatments (133 of 184;
72%). The median EBRT dose was 61.2 Gy (range, 18–
75.2 Gy), mostly delivered on a daily basis (median 33
fractions; range, 15–58 fractions). The most common sites
treated with Gamma Knife stereotactic radiosurgery were
the cavernous sinus (52 of 215; 24%) and the skull base
(47 of 215; 22%). Nearly half the patients received con-
current chemotherapy with EBRT (85 of 184; 46%). Six-
teen percent of patients (30 of 184) had documentation of
prior EBRT.
Stereotactic radiosurgery dose
Most treatments were prescribed to the 50% isodose
line with a median dose of 14 Gy (Table 2). The median
longest diameter treated was 45.3 mm and the median
maximum stereotactic radiosurgery dose (100% isodose
line) was 30 Gy. The median tumor volume was 15.9 cc
(range, 5.9–175.9 cc). A median of 9 isocenters were
used to treat the tumor volumes. There was no influence
of treatment intent on Gamma Knife stereotactic radiosur-
gery parameters, so these have not been reported
separately.
Local control
Median follow-up from the date of stereotactic radio-
surgery treatment was 17.3 months (range, 0.1–46
months). Local control at 12 months was 82% (see Fig-
ures 1C and 1D for an example of sustained successful
treatment), although 56 patients did eventually experience
local failure and 15 patients experienced marginal failure
(see Figures 1A and 1B for an example of marginal fail-
ure). Local control was statistically different (log-rank
p5 .002) among patients stratified by treatment type and
intent (EBRT1 stereotactic radiosurgery boost, salvage
stereotactic radiosurgery alone with curative intent, and
palliative stereotactic radiosurgery alone). EBRT1 stereo-
tactic radiosurgery boost had the best local control (88%
at 12 months) compared with stereotactic radiosurgery
salvage alone and palliative stereotactic radiosurgery.
There was no difference in 12-month local control
between salvage stereotactic radiosurgery alone with cura-
tive intent and palliative stereotactic radiosurgery alone
(73% vs 75%, respectively). In the patients who received
EBRT1 stereotactic radiosurgery boost, there was no
statistically significant difference in local control when
stratified by the timing of stereotactic radiosurgery boost
(before, during, or after EBRT; local control at 12 months
ranged from 75% to 92%, but the number of patients was
small in each group, likely accounting for the lack of sta-
tistical power). The use of chemotherapy had no effect on
local control (p5 .83). Paradoxically, patients who had
had prior surgery had poorer local control at 1 year
(p5 .013; 78% vs 83% at 1 year).
Of the 215 sites treated, 23 marginal failures occurred
(Table 3). Most marginal failures occurred in patients
who had recurrent disease (20 of 23 patients) who
received palliative stereotactic radiosurgery alone (12 of
23 patients). Sites of failure were most commonly in the
bony sinuses (ethmoid, maxillary) and in the cavernous
sinus (12 of 23).
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Late toxicity
Sixty-nine events were coded as late effects among 59
patients (Table 4). Median time to the development of
late effects was 17.7 months. Late effects were highly
varied depending on the anatomic area treated, but the
most common ones included radiation necrosis of the
brain (15 of 69; 22%) and cranial nerve palsies (11 of 69;
16%). Only new cranial neuropathies that occurred after
stereotactic radiosurgery treatment in the absence of
preceding deficits from surgery, prior EBRT, or tumor
progression were coded as late toxicities. The most com-
monly treated areas were the cavernous sinus (17 of 59;
29%) and the nasopharynx (12 of 59; 20%). Most late
effects were grade 1 and 2 toxicities, mostly asymptom-
atic cranial neuropathies or radiation necrosis. There were
14 grade 3 and above toxicities. There were 11 grade 3
toxicities, which consisted of 5 cases of resection for
symptomatic radiation necrosis, 3 cases of severe osteo-
necrosis requiring debridement, 2 cases of severe hearing
loss requiring cochlear implants, and 1 case of stroke. All
grade 4 toxicities (3 of 3) were complete blindness sec-
ondary to stereotactic radiosurgery. In actuarial terms, the
late complication (all events grades 1–4) incidence at 1
year was 12%, at 5 years it was 25%, and by 10 years it
was 26%. Most complications occurred within the first 5
years after Gamma Knife stereotactic radiosurgery treat-
ment. However, the risk of grade 3 and above late effects
increased significantly beyond 5 years. The actuarial risk
of grade 3 and above late effects was only 5% in the first
12 months but increased to 15% at 24 months and 40%
by 48 months.
Stereotactic radiosurgery dose parameters, such as mar-
ginal dose, tumor volume, or tumor diameter, were not
correlated with the development of late toxicity. Stereo-
tactic radiosurgery target site or treated location also had
no bearing on late toxicity. The use of chemotherapy
(p< .004) and prior surgery (p< .001) were correlated
with late toxicity development, but repeat EBRT was not
(p5 .20).
Survival
Overall survival from the date of initial diagnosis in all
patients was 41% at 12 months with a median survival of 9
months. Overall survival and progression-free survival from
the end of stereotactic radiosurgery treatment were 16% and
57% at 12 months, respectively. Median overall survival
and progression-free survival post-stereotactic radiosurgery
treatment was 3 months and 16 months, respectively. Poor
overall survival posttreatment likely reflects the large num-
ber of patients who were treated for recurrence and for palli-
ation. When patients were stratified by treatment intent
(EBRT1 stereotactic radiosurgery boost, salvage stereotac-
tic radiosurgery alone with curative intent, and palliative ste-
reotactic radiosurgery alone), those who received a boost
with EBRT had a much higher median progression-free sur-
vival (39 months; log-rank p5 .0001). Median progression-
free survival postsalvage stereotactic radiosurgery treatment
alone with curative intent was 16.1 months, whereas patients
treated with palliative stereotactic radiosurgery alone had a
median progression-free survival of 8 months. Interestingly,
patients treated with salvage stereotactic radiosurgery alone
TABLE 1. Patient demographics.
Sex N5 184
Male 115
Female 69
Median age at stereotactic
radiosurgery in years
62 (range,
25–98)
Histology N5 184
Squamous cell carcinoma 81
Salivary carcinoma 50
Nasopharyngeal carcinoma 26
Esthesioneuroblastoma 13
Other (sarcoma, neuroendocrine,
basal cell carcinoma)
14
Grade N5 184
High/intermediate/low/unknown
or not applicable
61/16/13/94
Local disease status N5 215
Primary 67
Recurrent 148
Intent of stereotactic radiosurgery treatment N5 215
Boost with EBRT 109
Palliative stereotactic radiosurgery alone
(for symptom relief alone)
63
Salvage stereotactic radiosurgery alone
(with curative intent)
43
Stereotactic radiosurgery timing relative to EBRT N5 109
Stereotactic radiosurgery before EBRT course 41
Stereotactic radiosurgery during EBRT course 41
Stereotactic radiosurgery after EBRT course 21
Unknown 6
Median EBRT prescription dose N5 186
Dose 61.2 Gy (range,
18–75.2 Gy)
Repeat EBRT at time of stereotactic radiosurgery,
prior radical treatment
N5 215
Yes 30
No 98
Unknown 87
Prior head and neck surgery N5 184
Yes 133
No 51
Chemotherapy N5 184
Concurrent 85
Palliative 6
Adjuvant 2
None 57
Unknown 34
Mean stereotactic radiosurgery dose
based on treatment intent
Boost with EBRT 11.4 Gy (range,
8–18 Gy)
Palliative stereotactic radiosurgery alone
for symptom relief alone
14.3 Gy (range,
10–18 Gy)
Salvage stereotactic radiosurgery alone
(with curative intent)
15 Gy (range,
10–20 Gy)
Location treated with stereotactic radiosurgery N5 215
Cavernous sinus 52
Meckel’s cave 10
Clivus 6
Ethmoid/sphenoid/maxillary sinus 34
Skull base 47
Cranial nerve V 6
Nasopharynx 15
Other (cerebellopontine angle,
pterygopalatine fossa, infraorbital foramen)
45
Abbreviations: EBRT, external beam radiotherapy; Gy, Gray.
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with curative intent had the best median overall survival
(15.2 months; p5 .02), although boost stereotactic radiosur-
gery was similar at 9.4 months and palliative patients lived a
median of 6.6 months post-stereotactic radiosurgery treat-
ment. Histology and chemotherapy use had no impact on
overall survival or progression-free survival. Although sur-
gery had no impact on overall survival, prior surgery was
correlated with worse progression-free survival (p5 .0001;
52% vs 76% at 1 year).
DISCUSSION
This study represents one of the largest series of
patients with head and neck cancer treated with radiosur-
gery. Although the patient population is heterogeneous, as
were the sites treated, it provides valuable information on
the potential late effects of stereotactic radiosurgery treat-
ment in long term survivors. The majority of our patients
was referred for treatment of recurrent disease and most
received concurrent chemoradiotherapy with a stereotactic
radiosurgery boost, although a number did receive
curative-intent stereotactic radiosurgery salvage alone.
The combination of EBRT and stereotactic radiosurgery
boost resulted in a substantial median progression-free
survival of nearly 40 months. This is likely also related to
volume of disease before treatment and performance sta-
tus, although treatment intent did not influence the dose
or volume of tissue treated with Gamma Knife stereotac-
tic radiosurgery. Our overall survival outcome of 40% at
12 months is also reflective of our patient population,
which included predominantly palliative and recurrent
patients.
TABLE 2. Stereotactic radiosurgery dose characteristics (N5 215).
Median stereotactic
radiosurgery dose characteristics Value (range)
Maximum stereotactic
radiosurgery dose
30 Gy (24–40 Gy)
Volume treated 15.9 cc (5.9–175.9 cc)
Marginal stereotactic
radiosurgery prescription dose
(minimal tumor dose)
14 Gy (12–20 Gy)
Prescription isodose line 50% (25% to 70%)
Maximum diameter treated 45.3 mm (19.6–90 mm)
Number of stereotactic
radiosurgery isocenters
9 (1–22)
Abbreviation: Gy, Gray.
FIGURE 1. (A) Squamous cell carcinoma
boost; (B) marginal failure 1 year later
but local control of treated disease
encompassed by prescription 50% iso-
dose line (yellow) remained intact; (C)
adenocarcinoma boost in a different
patient; and (D) local control 3 years
later.
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Most prior studies have focused on particular histolo-
gies of head and neck cancers in the primary curative
treatment setting (initial diagnosis) as well as in the recur-
rent setting. Many of these studies demonstrate good local
control but with a moderate risk of cranial nerve neuropa-
thy and brain radionecrosis. Long-term follow-up is
essential for delineating late effects.
Firlik et al1 reported one of the first series of radiosur-
gery for recurrent head and neck cancers after prior sur-
gery and EBRT. Although follow-up was highly varied
for the 12 patients in this series (range, 3–35 months), no
late effects were documented, but the authors noted that
11 of 12 patients had cranial nerve deficits before stereo-
tactic radiosurgery salvage. Local control was reported as
a crude rate of 8 of 12 patients based on imaging
characteristics.1
Stereotactic radiosurgery boost has been reported for
the treatment of salivary tumors both in the curative pri-
mary setting and in the recurrent setting. Douglas et al2
published a series of 34 patients with salivary cancer
treated with a planned Gamma Knife stereotactic radio-
surgery boost after neutron radiotherapy. Forty-month
local control was significantly better in boosted patients
compared to historical controls who had received only
neutron radiotherapy, 82% versus 39% (p5 .04). At a
median follow-up of 20.5 months, 1 patient had died
because of an infection. Complications were similar
whether tumors were boosted or not, with most side
effects due to the neutron beam therapy (xerostomia, tris-
mus, skin fibrosis). Three patients developed radiation
necrosis.2 Lee et al3 reviewed a series of 8 patients with
16 salivary tumor skull base recurrences. Allowing for
salvage stereotactic radiosurgery, 2-year local freedom
from progression was 75%. Once again, radiation necrosis
was a documented complication (in this series, 1 of 8
patients). Similarly, a study from Japan examining 12
patients with recurrent adenoid cystic carcinoma at the
skull base reported crude local control rates of 10 of 12
patients with a median overall survival of 18 months.
However, there was no discussion of late effects.4
Stereotactic radiosurgery has been studied extensively
in the primary treatment of nasopharyngeal cancers. Mul-
tiple retrospective studies have demonstrated improved
local control ranging from 93% to 100% at 3 years for
stereotactic radiosurgery boost after radical EBRT (series
had doses ranging from 64.8–66 Gy) with concurrent
TABLE 4. Late toxicity (69 events in 59 patients).
Median time to late toxicity
17.7 mo (range,
0.9–127.8 mo)
Sex N5 59
Male 37
Female 22
Histology N5 59
Squamous cell carcinoma 26
Salivary carcinoma 15
Nasopharyngeal carcinoma 12
Esthesioneuroblastoma 4
Other (neuroendocrine,
basal cell carcinoma)
2
Location treated with Gamma Knife N5 59
Cavernous sinus 17
Meckel’s cave 1
Clivus 2
Ethmoid/sphenoid/maxillary sinus 7
Skull base 8
Cranial nerve V 4
Nasopharynx 12
Other (CPA, pterygopalatine
fossa, infraorbital foramen)
8
Recurrent vs primary vs metastatic N5 69
Recurrent 35
Primary 31
Metastatic 3
Intent of treatment N5 69
Stereotactic radiosurgery curative 15
Boost with EBRT 45
Stereotactic radiosurgery palliative 9
Type of toxicity N5 69
Xerostomia 4
Vocal cord paralysis 1
Stroke 1
Radiation necrosis (brain) 15
Ptosis 2
Pain 7
Infection 5
Endocrine abnormalities 2
Hearing loss 3
Fistula 2
Fibrosis 1
Facial numbness 8
Eustachian tube dysfunction 1
Dysphagia 1
Decreased vision 5
Cranial nerve palsy 11
CTCAE grading of late toxicity
1 24
2 31
3 11
4 3
Abbreviations: CPA, cerebellopontine angle; EBRT, external beam radiotherapy; CTCAE, Com-
mon Terminology Criteria for Adverse Events.
TABLE 3. Characteristics of marginal failures.
Location treated with Gamma Knife N5 23
Cavernous sinus 5
Meckel’s cave 3
Ethmoid/sphenoid/maxillary sinus 7
Skull base 3
Cranial nerve V 1
Other (cerebellopontine angle, orbital fossa) 4
Histology N5 23
Squamous cell carcinoma 8
Salivary cancers 11
Other (nasopharyngeal carcinoma,
esthesioneuroblastoma, skin cancer)
4
Recurrent vs primary vs metastatic N5 23
Recurrent 20
Primary 1
Metastatic 2
Intent of treatment N5 23
Stereotactic radiosurgery curative 4
Boost with EBRT 7
Stereotactic radiosurgery palliative 12
Median stereotactic radiosurgery dose 14 Gy (range,
10–20 Gy)
Median stereotactic radiosurgery
tumor volume
14.9 cc (range,
2.7–85.1 cc)
Abbreviations: EBRT, external beam radiotherapy; Gy, Gray.
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chemotherapy.5–8 Most series noted minimal late effects
after treatment, although follow-up ranged from 12 to 21
months. In a recent series from Stanford detailing such
treatment, late toxicity was documented in 14 of 82
patients, with the most common complication being radia-
tion necrosis (10 of 14 patients).6
Stereotactic radiosurgery also seems to be a good
option for recurrent nasopharyngeal cancer involving the
base of the skull. One series of 36 patients treated for
recurrent disease with EBRT (range, 20–60 Gy) followed
by stereotactic radiosurgery boost (range, 8–20 Gy)
reported a 3-year local control rate of 56% and a 5-year
OS of 49%.9 Eleven percent developed nasopharyngeal
necrosis, and 1 patient developed asymptomatic skull
base destruction.9 Another series of 47 patients with base
of skull lesions, including nasopharyngeal cancer, exam-
ined the use of stereotactic radiosurgery alone for salvage
(median stereotactic radiosurgery dose 12 Gy).10 A crude
local control rate of 69% was achieved at a median
follow-up of 9 months. Three of 59 patients developed
cranial nerve neuropathies.10 Another series of 10 patients
showed a local control of 100% with only 1 patient
developing a late effect (new cranial neuropathy in the
absence of disease progression).11
Given these heterogeneous reports, our local control
rate of 82% is quite comparable to the published litera-
ture. In our series, the most common late effects were
radiation necrosis of the brain and cranial nerve deficits.
These accounted for more than 20% of all late effects.
Most late complications occurred within the first 5 years
of treatment (5-year complication incidence of 26% on
actuarial analysis). The cavernous sinus was the most
commonly treated stereotactic radiosurgery site in our
series. A number of retrospective series have focused on
the treatment of these lesions and the rate of cranial neu-
ropathy has ranged from 0% to 10%.12–14 However, the
follow-up in these series has been quite short (<14
months). In our series, the median time to develop late
effects was 17.7 months. Our study has reasonable long-
term follow-up, such that we documented 59 patients of
184 developing late effects (crude complication rate of
32%). Our higher complication rate likely reflects the
effects of recurrent disease and greater morbidity with
prior treatment and trimodality salvage treatment (most
patients in our series received concurrent chemoradiother-
apy and stereotactic radiosurgery). Indeed, this is
reflected by the correlation of prior surgery and chemo-
therapy use with late effects. Our findings that surgery
was negatively associated with local control and
progression-free survival is paradoxical, but likely reflects
difficult to control recurrent disease that was initially
treated with surgery alone and which was then referred to
the Mayo Clinic, for salvage chemoradiation and stereo-
tactic radiosurgery boost.
Our study was limited by its retrospective nature. Key
issues to correlating predictive factors for late effects,
such as prior radiotherapy and radiotherapy dose, were
not easily addressed, especially if patients were treated
many years ago (early 1990s) before referral to our insti-
tution. This missing information impeded our ability to
calculate cumulative doses to normal structures. The lack
of accurate staging information of the initial primary
tumor was also a major limitation. Palliation of symptoms
with stereotactic radiosurgery was also not well-
documented and was excluded from our primary analysis.
In spite of these shortcomings, this study is valuable in
evaluating the long-term outcome as well as feasibility of
stereotactic radiosurgery in the setting of head and neck
cancers. Stereotactic radiosurgery is a well-tolerated pro-
cedure that provides good local tumor control, especially
for patients who are able to receive it as a boost in addi-
tion to chemoradiotherapy. Even in the salvage setting
using stereotactic radiosurgery alone, it seems to provide
good local control. However, this needs to be balanced
with long-term follow-up and evaluation of concurrent or
prior radiotherapy treatments as cranial nerve neuropa-
thies and radiation necrosis were fairly common compli-
cations of such treatment.
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